134 related articles for article (PubMed ID: 7808786)
1. Cross resistance relevance of the chemical structure of different anthracyclines in multidrug resistant cells.
Tapiero H; Nguyen-Ba G; Lampidis TJ
Pathol Biol (Paris); 1994 Apr; 42(4):328-37. PubMed ID: 7808786
[TBL] [Abstract][Full Text] [Related]
2. Can cytotoxic activity of anthracyclines be related to DNA damage?
Nishiyama M; Horichi N; Mazouzi Z; Bungo M; Saijo N; Tapiero H
Anticancer Drug Des; 1990 Feb; 5(1):135-9. PubMed ID: 2317255
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of the in vivo resistance to adriamycin and modulation by calcium channel blockers in mice.
Yin MB; Bankusli I; Rustum YM
Cancer Res; 1989 Sep; 49(17):4729-33. PubMed ID: 2758408
[TBL] [Abstract][Full Text] [Related]
4. Cellular pharmacology of MX2, a new morpholino anthracycline, in human pleiotropic drug-resistant cells.
Watanabe M; Komeshima N; Naito M; Isoe T; Otake N; Tsuruo T
Cancer Res; 1991 Jan; 51(1):157-61. PubMed ID: 1988080
[TBL] [Abstract][Full Text] [Related]
5. Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II.
Jensen PB; Jensen PS; Demant EJ; Friche E; Sørensen BS; Sehested M; Wassermann K; Vindeløv L; Westergaard O; Hansen HH
Cancer Res; 1991 Oct; 51(19):5093-9. PubMed ID: 1655244
[TBL] [Abstract][Full Text] [Related]
6. Modulation of doxorubicin-induced DNA lesions by verapamil, DMDP and dipyridamole in resistant P388 cell lines.
Yin MB; Bankusli I; Frank C; Rustum YM
Anticancer Res; 1990; 10(2A):327-32. PubMed ID: 2346306
[TBL] [Abstract][Full Text] [Related]
7. Trifluoperazine modulation of resistance to the topoisomerase II inhibitor etoposide in doxorubicin resistant L1210 murine leukemia cells.
Kamath N; Grabowski D; Ford J; Drake F; Kerrigan D; Pommier Y; Ganapathi R
Cancer Commun; 1991 Feb; 3(2):37-44. PubMed ID: 1995027
[TBL] [Abstract][Full Text] [Related]
8. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacokinetics and action mechanism of anthracyclines].
Fukushima T; Ueda T; Nakamura T
Gan To Kagaku Ryoho; 1992 Apr; 19(4):445-50. PubMed ID: 1558393
[TBL] [Abstract][Full Text] [Related]
10. Intracellular accumulation and cytotoxic effect of (8-thiotheophyllinate) (triphenylphosphine) gold(I) in Friend leukemia cells.
Arizti MP; Garcia-Orad A; Sommer F; Silvestro L; Massiot P; Chevallier P; Gutiérrez-Zorrilla JM; Colacio E; Martinez de Pancorbo M; Tapiero H
Anticancer Res; 1991; 11(2):625-8. PubMed ID: 2064317
[TBL] [Abstract][Full Text] [Related]
11. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
[TBL] [Abstract][Full Text] [Related]
12. Modulation of the antioxidant activities in dox-sensitive and -resistant Friend leukemia cells. Effect of doxorubicin.
Crescimanno M; D'Alessandro N; Armata MG; Toulmond S; Tapiero H
Anticancer Res; 1991; 11(2):901-3. PubMed ID: 2064348
[TBL] [Abstract][Full Text] [Related]
13. 3'-Deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin conquers multidrug resistance by rapid influx following higher frequency of formation of DNA single- and double-strand breaks.
Horichi N; Tapiero H; Sugimoto Y; Bungo M; Nishiyama M; Fourcade A; Lampidis TJ; Kasahara K; Sasaki Y; Takahashi T
Cancer Res; 1990 Aug; 50(15):4698-701. PubMed ID: 2164445
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy of a phenothiazine and a bisquinaldinium calmodulin antagonist against multidrug-resistant P388 cell lines.
Hait WN; Pierson NR
Cancer Res; 1990 Feb; 50(4):1165-9. PubMed ID: 2297765
[TBL] [Abstract][Full Text] [Related]
15. Paradoxical increase in DNA cross-linking in a human ovarian carcinoma cell line resistant to cyanomorpholino doxorubicin.
Lau DH; Ross KL; Sikic BI
Cancer Res; 1990 Jul; 50(13):4056-60. PubMed ID: 2162251
[TBL] [Abstract][Full Text] [Related]
16. Drug sensitivity of heat-resistant mouse B16 melanoma variants.
Kroll DJ; Borgert CJ; Wiedmann TW; Rowe TC
Radiat Res; 1990 Oct; 124(1):15-21. PubMed ID: 2236492
[TBL] [Abstract][Full Text] [Related]
17. Effects of daunorubicin and doxorubicin, free and associated with DNA, on hemopoietic stem cells.
Huybrechts M; Symann M; Trouet A
Cancer Res; 1979 Sep; 39(9):3738-43. PubMed ID: 476697
[TBL] [Abstract][Full Text] [Related]
18. Decreased retention of actinomycin D as the basis for cross-resistance in anthracycline-resistant sublines of P388 leukemia.
Inaba M; Johnson RK
Cancer Res; 1977 Dec; 37(12):4629-34. PubMed ID: 922743
[TBL] [Abstract][Full Text] [Related]
19. Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells.
Gosland MP; Lum BL; Sikic BI
Cancer Res; 1989 Dec; 49(24 Pt 1):6901-5. PubMed ID: 2582432
[TBL] [Abstract][Full Text] [Related]
20. Cross-resistance of human multidrug-resistant cells to mitomycin C.
Yusa K; Sato W; Yamazaki A; Tsukahara S; Tsuruo T
Anticancer Res; 1991; 11(3):1301-4. PubMed ID: 1909515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
